| Literature DB >> 17199031 |
Roger J Porter1, Virinder Nohria, Chris Rundfeldt.
Abstract
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maximal tolerated dose for most patients is 1,200 mg/day. Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At present, retigabine is in two pivotal phase III studies.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17199031 DOI： 10.1016/j.nurt.2006.11.012
Source DB: PubMed Journal: Neurotherapeutics ISSN： 1878-7479 Impact factor: 7.620